Catalyst Pharmaceuticals (NASDAQ:CPRX) Sees Unusually-High Trading Volume – Should You Buy?

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) saw an uptick in trading volume on Thursday . 5,312,735 shares changed hands during trading, an increase of 263% from the previous session’s volume of 1,464,761 shares.The stock last traded at $31.1250 and had previously closed at $30.52.

More Catalyst Pharmaceuticals News

Here are the key news stories impacting Catalyst Pharmaceuticals this week:

• Positive Sentiment: Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for about $4.1 billion, or $31.50 per share in cash, which is above where the stock had been trading and typically supports a takeover premium. Closing is expected in the third quarter of 2026. Italy’s Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1 billion
• Positive Sentiment: Catalyst also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs, pushing any potential generic competition to January 2035 and resolving all pending FIRDAPSE patent disputes. That reduces legal overhang for the business. Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE Patent Litigation with Hetero Labs Ltd.
• Neutral Sentiment: The company canceled its first-quarter 2026 conference call and webcast, which may have drawn attention but does not appear to be a major fundamental development on its own. Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast
• Negative Sentiment: Stephens downgraded Catalyst to Equal Weight from Overweight, which can weigh on sentiment even though the downgrade may be overshadowed by the acquisition bid. Stephens & Co. downgrades Catalyst Pharmaceuticals (CPRX)
• Negative Sentiment: Law firms announced shareholder investigations into whether Catalyst is receiving a fair price in the Angelini transaction, creating a small litigation-related overhang. Shareholder Alert: Ademi LLP investigates whether Catalyst Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CPRX. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Oppenheimer lowered shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Zacks Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Finally, Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $35.00 to $31.50 in a research note on Friday. Three investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.17.

Catalyst Pharmaceuticals Trading Down 0.1%

The stock’s fifty day moving average price is $25.31 and its 200 day moving average price is $23.93. The stock has a market cap of $3.81 billion, a P/E ratio of 18.43, a price-to-earnings-growth ratio of 1.01 and a beta of 0.72.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CPRX. Royal Bank of Canada increased its stake in Catalyst Pharmaceuticals by 39.1% in the first quarter. Royal Bank of Canada now owns 213,469 shares of the biopharmaceutical company’s stock valued at $5,177,000 after acquiring an additional 60,040 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Catalyst Pharmaceuticals by 5.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 72,052 shares of the biopharmaceutical company’s stock valued at $1,749,000 after acquiring an additional 3,800 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Catalyst Pharmaceuticals by 11.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after purchasing an additional 333,100 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Catalyst Pharmaceuticals by 99.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 526,297 shares of the biopharmaceutical company’s stock worth $12,763,000 after purchasing an additional 262,392 shares during the period. Finally, Intech Investment Management LLC raised its position in Catalyst Pharmaceuticals by 6.5% in the 1st quarter. Intech Investment Management LLC now owns 70,087 shares of the biopharmaceutical company’s stock worth $1,700,000 after purchasing an additional 4,261 shares during the period. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).